{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:35:01Z","timestamp":1793504101264,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Bisphosphonates are the mainstay drugs for osteoporosis, but in clinical practice, they are often ineffective due to low compliance. However, there have been few studies examining compliance on a product-by-product basis or in detail in Japan. This study aimed to clarify the bisphosphonate compliance from the viewpoints of product selection, formulation, and patient characteristics using medical insurance claim data in Japan, to generate useful knowledge for improving bisphosphonate compliance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Bisphosphonate records for osteoporosis treatment were extracted from Japanese medical insurance claim data (2021\u20132023), and the Medication Possession Ratio (MPR) of each patient was calculated from the records. The calculated MPR and compliance classification (Compliant\/Non-compliant\/Dropout) based on dispensing status were statistically analyzed from viewpoints of drug product, dose form\/frequency, and patient sex\/age to investigate the influence of each factor on compliance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The mean MPR for all patients (<jats:italic>N<\/jats:italic>\u2009=\u200963,197) was 76.7%. Product choice influenced compliance, with significance in 230 pairs among the 71 major products. Tablet was the most compliant formulation, and compliance was better with longer dose intervals. Women showed significantly better compliance and older age was associated with better compliance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study generated new data regarding product-specific MPRs, and clarified that product selection influences patient compliance. The study also supported previous findings that sex, age, and dose frequency influence compliance. It is expected that the findings of this study will be utilized for drug development, drug selection and patient guidance in clinical practice, to improve the treatment environment for osteoporosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40780-025-00434-5","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T17:06:57Z","timestamp":1744132017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bisphosphonate compliance in Japan from the perspective of product, formulation, and patient characteristics: analysis of medical insurance claim data"],"prefix":"10.1186","volume":"11","author":[{"given":"Kenji","family":"Kabeya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuyo","family":"Yanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"434_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1471-2474-8-97","volume":"8","author":"J Adachi","year":"2007","unstructured":"Adachi J, Lynch N, Middelhoven H, Hunjan M, Cowell W. The association between compliance and persistence with bisphosphonate therapy and fracture risk. BMC Musculoskelet Disord. 2007;8:97\u2013102. https:\/\/doi.org\/10.1186\/1471-2474-8-97","journal-title":"BMC Musculoskelet Disord"},{"key":"434_CR2","doi-asserted-by":"publisher","unstructured":"Modi A, Siris ES, Tang J, Sen S. Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy. Curr Med Res Opin. 2015;31(4):757\u2013 765. https:\/\/doi.org\/10.1185\/03007995.2015.1016605","DOI":"10.1185\/03007995.2015.1016605"},{"key":"434_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015626935","author":"SS Moser","year":"2016","unstructured":"Moser SS, Yu J, Goldshtein I, Ish-Shalom S, Rouach V, Shalev V, Modi A, Chodick G. Cost and Consequences of Nonadherence With Oral Bisphosphonate Therapy: Findings From a Real-World Data Analysis. Ann Pharmacother. 2016;50(4)262\u2013269. https:\/\/doi.org\/10.1177\/1060028015626935"},{"key":"434_CR4","doi-asserted-by":"publisher","unstructured":"Chodick G, Moser SS, Goldshtein I. Non-adherence with bisphosphonates among patients with osteoporosis: impacton fracture risk and healthcare cost. Expert Rev PharmacoEcon Outcomes Res. 2016;16(3):359\u2013370. https:\/\/doi.org\/10.1586\/14737167.2016.1171145","DOI":"10.1586\/14737167.2016.1171145"},{"key":"434_CR5","doi-asserted-by":"publisher","unstructured":"Eisenberg DF, Placzek H, Gu T, Krishna A, Tulsi BB. Cost and consequences of noncompliance to oral bisphosphonate treatment. J Managed Care Specialty Pharm. 2015;21(1):56\u201365. https:\/\/doi.org\/10.18553\/jmcp.2015.21.1.56","DOI":"10.18553\/jmcp.2015.21.1.56"},{"issue":"12","key":"434_CR6","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1007\/s00198-016-3683-7","volume":"27","author":"J Kjellberg","year":"2016","unstructured":"Kjellberg J, Jorgensen AD, Vestergaard P, Ibsen R, Gerstoft F, Modi A. Cost and health care resource use associated with noncompliance with oral bisphosphonate therapy: an analysis using Danish health registries. Osteoporos Int. 2016;27(12):3535\u20133541. https:\/\/doi.org\/10.1007\/s00198-016-3683-7","journal-title":"Osteoporos Int"},{"key":"434_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40360-020-00430-5","volume":"21","author":"J-P Rothen","year":"2020","unstructured":"Rothen J-P, Rutishauser J, Walter PN, Hersberger KE, Isabelle Arnet. Oral intermittent vitamin D substitution: influence of pharmaceutical form and dosage frequency on medication adherence: a randomized clinical trial. BMC Pharmacol Toxicol. 2020;21:51. https:\/\/doi.org\/10.1186\/s40360-020-00430-5.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"22","key":"434_CR8","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1055\/s-2006-946559","volume":"131","author":"R Bartl","year":"2006","unstructured":"Bartl R, G\u00f6tte S, Hadji P, Hammerschmidt T. Adh\u00e4renz Mit T\u00e4glichen und W\u00f6chentlichen oralen bisphosphonaten in der osteoporosetherapie. Dtsch Med Wochenschr. 2006;131(22):1257\u20131262. https:\/\/doi.org\/10.1055\/s-2006-946559","journal-title":"Dtsch Med Wochenschr"},{"key":"434_CR9","doi-asserted-by":"publisher","unstructured":"Hadji P, Jacob L, Kostev K. Gender- and age-related treatment compliance in patients with osteoporosis in Germany. Patient Preference and Adherence. 2016;10:1379\u20132385. https:\/\/doi.org\/10.2147\/PPA.S118396","DOI":"10.2147\/PPA.S118396"},{"key":"434_CR10","doi-asserted-by":"publisher","unstructured":"Cheng L-I, Durden E, Limone B, Radbill L, Juneau PL, Spangler L, Mirza FM, Stolshek BS. Persistance and compliance with osteroporosis therapies among women in a commercially insured population in the united States. J Managed Care Specialty Pharm. 2015;21(9):824\u2013833a. https:\/\/doi.org\/10.18553\/jmcp.2015.21.9.824","DOI":"10.18553\/jmcp.2015.21.9.824"},{"key":"434_CR11","doi-asserted-by":"publisher","unstructured":"Nakatoh S, Fujimori K, Ishii S, Tamaki J, Okimoto N, Ogawa S, Iki M. Insufficient persistence to pharmacotherapy in Japanese patients with osteoporosis: an analysis of the National database of health insurance claims and specific health checkups in Japan. Archives Osteoporos. 2021;16:131. https:\/\/doi.org\/10.1007\/s11657-021-00993-8","DOI":"10.1007\/s11657-021-00993-8"},{"key":"434_CR12","doi-asserted-by":"publisher","unstructured":"Kosaka Y, Sugiyama T, Hara K, Kobayashi Y. Adherence to daily, weekly, and monthly dosing regimens of bisphosphonates for osteoporosis treatment in postmenopausal women in Japan: A retrospective study using claims data. Tohoku J Exp Med. 2021;255(2):147\u2013155. https:\/\/doi.org\/10.1620\/tjem.255.147","DOI":"10.1620\/tjem.255.147"},{"issue":"19","key":"434_CR13","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.3390\/jcm10194350","volume":"10","author":"H Lee","year":"2021","unstructured":"Lee H, Lee S, Kim D, Cho w, Cho S, Yoon S, Lee S. Effect of dosing interval on compliance of osteoporosis patients on bisphosphonate therapy: observational study using nationwide insurance claims data. J Clin Med. 2021;10(19):4350. https:\/\/doi.org\/10.3390\/jcm10194350","journal-title":"J Clin Med"},{"key":"434_CR14","doi-asserted-by":"publisher","unstructured":"Durden E, Pinto L, Lopez-Gonzalez L, Juneau P, Barron R. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the united States. Archives Osteoporos. 2017;12:22. https:\/\/doi.org\/10.1007\/s11657-017-0316-5","DOI":"10.1007\/s11657-017-0316-5"},{"issue":"10","key":"434_CR15","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1185\/030079907X226339","volume":"23","author":"SR Earnshaw","year":"2007","unstructured":"Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Curr Med Res Opin. 2007;23(10):2517\u20132529. https:\/\/doi.org\/10.1185\/030079907X226339","journal-title":"Curr Med Res Opin"},{"key":"434_CR16","doi-asserted-by":"publisher","unstructured":"Kao C-C, Hsieh H-M, Lee DY, Hsieh K-P, Sheu S-J. Importance of medication adherence in treatment needed diabetic retinopathy. Sci Rep. 2021;11:19100. https:\/\/doi.org\/10.1038\/s41598-021-98488-6","DOI":"10.1038\/s41598-021-98488-6"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00434-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-025-00434-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00434-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T17:26:31Z","timestamp":1744219591000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-025-00434-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["434"],"URL":"https:\/\/doi.org\/10.1186\/s40780-025-00434-5","relation":{"references":[{"id-type":"doi","id":"10.1177\/1060028015626935","asserted-by":"subject"}]},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as JMDC Inc. ensured that the data was sufficiently anonymized and formal consent was not considered required for this retrospective study. This study was approved by Research Ethics Committee of the Faculty of Pharmaceutical Sciences of the University of Tokyo (approval number: 6\u201312), in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable, as JMDC Inc. ensured that the data was sufficiently anonymized.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KK: No conflicts to be declared. HS, NY, and YS: Members of an endowed laboratory funded by companies including Ain Pharmaciez Inc., I & H Co., Ltd., Medical Ikkou Co., Ltd., Toho Holdings Co., Ltd., Tomod\u2019s, and Wakaba Co. The companies are not directly involved in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}